INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

ATHALeonaBio, Inc.

CIK 0001620463

EDGAR filingsOpen in network
Disclosed transactions27
Buys / sells2 / 2
Max Insider Score53
Connections12with evidence

ATHA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
53
PJ
Portman David J.10% Owner
LONALeonaBio, Inc.
Open-market purchase
BUY$17.33B
5.50M sh
Oct 26, 2026Oct 28, 2026
traded Oct 26, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Portman David J.10% Owner · Oct 28, 2026
  • ← Insider ofevidence
    Callori FredDirector · May 7, 2026
  • ← Insider ofevidence
    Silverman Peter B.Director · May 7, 2026
53
PJ
Portman David J.10% Owner
LONALeonaBio, Inc.
Open-market purchase
BUY
$9.92B
3.15M sh
Oct 26, 2026
Oct 28, 2026
traded Oct 26, 2026
+2d
SEC FORM 4

Evidence

9
CF
Callori FredDirector
LONALeonaBio, Inc.
Grant or award
A—
2,333 sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
KB
Kosacz BarbaraDirector
LONALeonaBio, Inc.
Grant or award
A—
28.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
SB
Silverman Peter B.Director
LONALeonaBio, Inc.
Grant or award
A—
2,333 sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
RA
Romano Kelly ADirector
LONALeonaBio, Inc.
Grant or award
A—
28.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

9
SB
Silverman Peter B.Director
LONALeonaBio, Inc.
Grant or award
A—
56.0K sh
May 5, 2026May 7, 2026
traded May 5, 2026
+2dSEC FORM 4

Evidence

9
CF
Callori FredDirector
LONALeonaBio, Inc.
Grant or award
A—
56.0K sh
May 5, 2026May 7, 2026
traded May 5, 2026
+2dSEC FORM 4

Evidence

9
LJ
Litton Mark JamesDirector, PRESIDENT and CEO
LONALeonaBio, Inc.
Grant or award
A—
750.0K sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

5
RR
Renninger RobertCHIEF FINANCIAL OFFICER
LONALeonaBio, Inc.
Grant or award
A—
300.0K sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

9
CK
Church KevinCHIEF SCIENTIFIC OFFICER
LONALeonaBio, Inc.
Grant or award
A—
300.0K sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

9
KB
Kosacz BarbaraDirector
LONALeonaBio, Inc.
Grant or award
A—
28.0K sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

9
RA
Romano Kelly ADirector
LONALeonaBio, Inc.
Grant or award
A—
28.0K sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

9
PA
Panzara Michael A.Director
LONALeonaBio, Inc.
Grant or award
A—
28.0K sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

9
WM
Worthington MarkGENERAL COUNSEL and CCO
LONALeonaBio, Inc.
Grant or award
A—
300.0K sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

9
SJ
San Martin JavierCHIEF MEDICAL OFFICER
LONALeonaBio, Inc.
Grant or award
A—
350.0K sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

31
RR
Renninger RobertCHIEF FINANCIAL OFFICER
LONALeonaBio, Inc.
Open-market sale
SELL$4,865
906 sh
Mar 4, 2026Mar 5, 2026
traded Mar 4, 2026
+1dSEC FORM 4

Evidence

13
RR
Renninger RobertCHIEF FINANCIAL OFFICER
LONALeonaBio, Inc.
Option exercise
M—
3,900 sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

5
RR
Renninger RobertCHIEF FINANCIAL OFFICER
LONALeonaBio, Inc.
Option exercise
M—
3,900 sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

19
RR
Renninger RobertChief Financial Officer
ATHALeonaBio, Inc.
Option exercise
M—
1,236 sh
Dec 31, 2025Jan 5, 2026
traded Dec 31, 2025
+5dSEC FORM 4

Evidence

28
RR
Renninger RobertChief Financial Officer
ATHALeonaBio, Inc.
Grant or award
A$2,310
1,000 sh
Nov 18, 2025Jan 5, 2026
traded Nov 18, 2025
+48dSEC FORM 4

Evidence

15
RR
Renninger RobertChief Financial Officer
ATHALeonaBio, Inc.
Option exercise
M—
1,236 sh
Dec 31, 2025Jan 5, 2026
traded Dec 31, 2025
+5dSEC FORM 4

Evidence

31
RR
Renninger RobertChief Financial Officer
ATHALeonaBio, Inc.
Open-market sale
SELL$2,043
297 sh
Jan 2, 2026Jan 5, 2026
traded Jan 2, 2026
+3dSEC FORM 4

Evidence

15
RR
Renninger RobertChief Financial Officer
ATHALeonaBio, Inc.
Grant or award
A—
34.4K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC FORM 4

Evidence

15
SJ
San Martin JavierCHIEF MEDICAL OFFICER
ATHALeonaBio, Inc.
Grant or award
A—
44.5K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC FORM 4

Evidence

15
CK
Church KevinCHIEF SCIENTIFIC OFFICER
ATHALeonaBio, Inc.
Grant or award
A—
35.1K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC FORM 4

Evidence

15
WM
Worthington MarkGeneral Counsel and CCO
ATHALeonaBio, Inc.
Grant or award
A—
34.4K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC FORM 4

Evidence

← Insider ofevidence
Kosacz Barbara
Director · Apr 13, 2026
  • ← Insider ofevidence
    Romano Kelly ADirector · Apr 13, 2026
  • ← Insider ofevidence
    Panzara Michael A.Director · Apr 13, 2026
  • ← Insider ofevidence
    Litton Mark JamesDirector, PRESIDENT and CEO · Apr 13, 2026
  • ← Insider ofevidence
    San Martin JavierCHIEF MEDICAL OFFICER · Dec 29, 2025
  • ← Insider ofevidence
    Renninger RobertChief Financial Officer · Dec 29, 2025
  • ← Insider ofevidence
    Worthington MarkGeneral Counsel and CCO · Dec 29, 2025
  • ← Insider ofevidence
    Church KevinCHIEF SCIENTIFIC OFFICER · Dec 29, 2025
    • Source error

    Price history for ATHA is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.